Summary
Pfizer Inc. (PFE) announced a significant addition to its Board of Directors with the election of Dr. Susan Hockfield, effective March 3, 2020. Dr. Hockfield's extensive experience in science and technology is expected to bolster the company's strategic direction, particularly given her appointments to the Regulatory and Compliance Committee and the Science and Technology Committee. This move signifies Pfizer's continued commitment to strengthening its leadership with individuals possessing deep scientific expertise, which is crucial for navigating the complex landscape of drug development and regulatory approval.
Key Highlights
- 1Pfizer Inc. elected Dr. Susan Hockfield to its Board of Directors, effective March 3, 2020.
- 2Dr. Hockfield's appointment strengthens the Board's scientific and technological expertise.
- 3She has been appointed to the Regulatory and Compliance Committee.
- 4She has also been appointed to the Science and Technology Committee.
- 5Dr. Hockfield will receive compensation according to the company's standard non-employee director arrangements.
- 6An indemnification agreement has been provided to Dr. Hockfield.
- 7The announcement was made via a press release dated March 4, 2020, attached as an exhibit.